hCG, or human chorionic gonadotropin, is a hormone built from two joined protein chains. One chain is shared with three other hormones. The second is unique to hCG. Labs study how it acts on the LH/CG receptor in fertility and hormone research. hCG does not cause weight loss.
Reviewed August 22, 2026 · Artemis Labs
What is hCG?
hCG (human chorionic gonadotropin) is a heterodimeric glycoprotein hormone composed of an α-subunit (92 amino acids, shared with LH, FSH, and TSH) and a β-subunit (145 amino acids, unique to hCG; confers LHCGR specificity). The Artemis Labs research peptide is supplied for in-vitro and pre-clinical laboratory study of LH/CG-receptor (LHCGR) pharmacology, gonadotropin biology, and hypothalamic-pituitary-gonadal axis research.
Is Artemis Labs hCG the same as Pregnyl, Novarel or Ovidrel?
Supplied strictly as a research reagent — not as a therapeutic equivalent of the FDA-approved parent compound (Pregnyl, Novarel, Ovidrel).
The hCG parent compound is FDA-approved for specific human indications (female ovulation induction, male hypogonadotropic hypogonadism, cryptorchidism in prepubertal males) under brand names Pregnyl, Novarel, Ovidrel. The Artemis Labs research peptide is supplied strictly as a research reagent for laboratory research and is not equivalent to those approved drug products.
Does hCG cause weight loss?
Critical framing notice — hCG is not a weight-loss research compound. Comprehensive meta-analytic evidence published in 1995 (Lijesen et al., British Journal of Clinical Pharmacology, PMID 8527285) and a follow-up clinical analysis in 2013 (Goodbar et al., Annals of Pharmacotherapy, PMID 23606549) established that hCG produces no weight loss beyond what is attributable to severe calorie restriction. The FDA has issued explicit warning letters declaring “HCG Diet Products Are Illegal.” Artemis Labs does not position hCG for weight-loss research and does not market its product for that use.
What is hCG actually studied for?
Legitimate 2024–2025 peer-reviewed research applications centre on hypogonadism and fertility research models. Alexander et al. 2024 (European Journal of Endocrinology, PMID 38128110) systematically reviewed gonadotropins for pubertal induction in males with hypogonadotropic hypogonadism. Grob et al. 2024 (Journal of Paediatrics and Child Health, PMID 38572627) documented long-term fertility outcomes in male adults with congenital hypogonadotropic hypogonadism treated during puberty with hCG and recombinant FSH. Muir et al. 2025 (Clinical Endocrinology, PMID 39445789) provides the most recent meta-analysis on gonadotropin treatment for spermatogenesis induction in pathologic gonadotropin deficiency.
What is the regulatory and anti-doping status of hCG?
Regulatory context: hCG is on the WADA Prohibited List for male athletes (S2 class: Peptide hormones, growth factors, related substances and mimetics) — prohibited at all times for males. This is factual regulatory context; Artemis Labs does not market hCG for athletic-performance use. Each vial ships with a lot-specific Certificate of Analysis confirming identity (mass spectrometry / SDS-PAGE), purity (HPLC where applicable), and source (urinary-derived uhCG or recombinant rhCG). For laboratory research use only — no human dosing, administration, therapeutic, diagnostic, preventative, weight-loss, or fertility-treatment claim is made.
What does the hCG evidence not show?
- No weight-loss effect. The 1995 Lijesen meta-analysis and the 2013 Goodbar follow-up found no scientific evidence that hCG produces weight loss beyond severe calorie restriction, and the FDA has declared HCG diet products illegal.
- The supporting research is in gonadotropin-deficient populations. Alexander 2024, Grob 2024 and Muir 2025 all studied hypogonadotropic hypogonadism or pathologic gonadotropin deficiency. Those findings do not generalise to people with normal gonadotropin function.
- The molecule is not one fixed thing. hCG is supplied as either urinary-derived (uhCG) or recombinant (rhCG) material and its molecular weight varies with glycosylation, so lot-to-lot comparability has to be read off the COA.
- The FDA-approved products are different products. Pregnyl, Novarel and Ovidrel are approved drug products; the Artemis Labs research reagent is not a therapeutic equivalent of any of them.
How does Artemis Labs verify hCG identity and purity?
Every lot is verified by a third party — purity by reverse-phase HPLC where applicable, identity by mass spectrometry and SDS-PAGE — and the lot-specific Certificate of Analysis, which also states the source form (uhCG or rhCG), ships with every order.
Analytical Specifications
| Property | Value |
|---|---|
| Class | Heterodimeric glycoprotein hormone; LH/CG receptor (LHCGR) agonist |
| α-subunit | 92 amino acids, glycosylated; shared with LH, FSH and TSH |
| β-subunit | 145 amino acids, unique to hCG; confers LHCGR specificity |
| Molecular weight | ~36,700 g/mol (intact heterodimer, varies with glycosylation) |
| CAS number | 9002-61-3 |
| Source | Urinary-derived (uhCG) or recombinant (rhCG) — batch COA specifies |
| Purity | ≥99% by RP-HPLC where applicable; identity confirmed by MS / SDS-PAGE |
| Form | Lyophilised powder; vial fill stated on the lot-specific COA |
| Storage | −20 °C, desiccated, protected from light |
| Endotoxin | Tested ≤ 0.5 EU/mg (LAL assay; lot-specific) |
References
- Lijesen GK, Theunissen IM, Lems WF, et al. (1995). The effect of human chorionic gonadotropin (HCG) in the treatment of obesity by means of the Simeons therapy: a criteria-based meta-analysis. British Journal of Clinical Pharmacology. PMID 8527285 · DOI 10.1111/j.1365-2125.1995.tb05779.x
- Goodbar NH, Foushee JA, Eagerton DH, et al. (2013). Effect of the human chorionic gonadotropin diet on patient outcomes. Annals of Pharmacotherapy. PMID 23606549 · DOI 10.1345/aph.1R755
- Alexander EC et al. (2024). Gonadotropins for pubertal induction in males with hypogonadotropic hypogonadism: systematic review and meta-analysis. European Journal of Endocrinology. PMID 38128110 · DOI 10.1093/ejendo/lvad166
- Grob F et al. (2024). Fertility outcomes in male adults with congenital hypogonadotropic hypogonadism treated during puberty with human chorionic gonadotropin and recombinant follicle stimulating hormone. Journal of Paediatrics and Child Health. PMID 38572627 · DOI 10.1111/jpc.16540
- Muir CA et al. (2025). Efficacy of Gonadotropin Treatment for Induction of Spermatogenesis in Men With Pathologic Gonadotropin Deficiency: A Meta-Analysis. Clinical Endocrinology (Oxford). PMID 39445789 · DOI 10.1111/cen.15151




Reviews
There are no reviews yet.